Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 May;27(5):547–552. doi: 10.1111/j.1365-2125.1989.tb03416.x

A comparison of the effects of flosequinan, a new vasodilator, and propranolol on sub-maximal exercise in healthy volunteers.

H M Lewis 1, M J Kendall 1, S R Smith 1, J R Bratty 1
PMCID: PMC1379919  PMID: 2757879

Abstract

1. The effects of steady state flosequinan, a new vasodilator, and propranolol, on glucose mobilisation, lipolysis and plasma potassium concentration during sub-maximal exercise testing were investigated in a double-blind, randomised, three-way crossover study in 12 healthy volunteers. 2. Plasma glucose, potassium and free fatty acid concentration during and after exercise on flosequinan were similar to those on placebo. Exercise heart rates were 7% (+9.2 beats min-1) higher on flosequinan compared with placebo (P less than 0.05). During exercise on propranolol plasma glucose concentrations were comparable with those on placebo but plasma potassium concentrations were higher (mean increase 0.26 mmol l-1, P less than 0.01) whereas free fatty acid concentrations were lower (mean decrease 0.10 mmol 1-1, P less than 0.01). As expected the heart rate on exercise was 25% less (-35 beats min-1) on propranolol (P less than 0.05). 3. These data suggest that, in contrast to propranolol, flosequinan does not adversely affect the mobilisation of the two major sources of energy during sub-maximal exercise.

Full text

PDF
547

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carlsson E., Fellenius E., Lundborg P., Svensson L. beta-Adrenoceptor blockers, plasma-potassium, and exercise. Lancet. 1978 Aug 19;2(8086):424–425. doi: 10.1016/s0140-6736(78)91893-7. [DOI] [PubMed] [Google Scholar]
  2. Cowley A. J., Wynne R. D., Stainer K., Fullwood L., Rowley J. M., Hampton J. R. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects. BMJ. 1988 Jul 16;297(6642):169–173. doi: 10.1136/bmj.297.6642.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Epstein F. H., Rosa R. M. Adrenergic control of serum potassium. N Engl J Med. 1983 Dec 8;309(23):1450–1451. doi: 10.1056/NEJM198312083092308. [DOI] [PubMed] [Google Scholar]
  4. Gross S. R., Mayer S. E. Regulation of phosphorylase B to A conversion in muscle. Life Sci. 1974 Feb 1;14(3):401–414. doi: 10.1016/0024-3205(74)90355-5. [DOI] [PubMed] [Google Scholar]
  5. Hall P. E., Kendall M. J., Smith S. R. Beta blockers and fatigue. J Clin Hosp Pharm. 1984 Dec;9(4):283–291. doi: 10.1111/j.1365-2710.1984.tb01089.x. [DOI] [PubMed] [Google Scholar]
  6. Hall P. E., Smith S. R., Kendall M. J. The effect of propranolol on the rise in plasma ammonia during modest exercise. Eur J Clin Pharmacol. 1987;32(2):149–151. doi: 10.1007/BF00542187. [DOI] [PubMed] [Google Scholar]
  7. Hall P. E., Smith S. R., Kendall M. J. The effects of four beta-adrenoceptor antagonists during modest exercise on plasma ammonia and heart rate. Clin Sci (Lond) 1987 Jun;72(6):679–682. doi: 10.1042/cs0720679. [DOI] [PubMed] [Google Scholar]
  8. Kessler P. D., Packer M. Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. Am Heart J. 1987 Jan;113(1):137–143. doi: 10.1016/0002-8703(87)90021-4. [DOI] [PubMed] [Google Scholar]
  9. Kullmer T., Kindermann W. Physical performance and serum potassium under chronic beta-blockade. Eur J Appl Physiol Occup Physiol. 1985;54(4):350–354. doi: 10.1007/BF02337177. [DOI] [PubMed] [Google Scholar]
  10. Leenen F. H., Coenen C. H., Zonderland M., Maas A. H. Effects of cardioselective and nonselective beta-blockade on dynamic exercise performance in mildly hypertensive men. Clin Pharmacol Ther. 1980 Jul;28(1):12–21. doi: 10.1038/clpt.1980.124. [DOI] [PubMed] [Google Scholar]
  11. Lundborg P., Aström H., Bengtsson C., Fellenius E., von Schenck H., Svensson L., Smith U. Effect of beta-adrenoceptor blockade on exercise performance and metabolism. Clin Sci (Lond) 1981 Sep;61(3):299–305. doi: 10.1042/cs0610299. [DOI] [PubMed] [Google Scholar]
  12. Macdonald I. A., Bennett T., Brown A. M., Wilcox R. G., Skene A. M. The effects of acute or chronic ingestion of propranolol or metoprolol on the metabolic and hormonal responses to prolonged, submaximal exercise in hypertensive men. Br J Clin Pharmacol. 1984 Mar;17(3):283–293. doi: 10.1111/j.1365-2125.1984.tb02343.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pearson S. B., Banks D. C., Patrick J. M. The effect of beta-adrenoceptor blockade on factors affecting exercise tolerance in normal man. Br J Clin Pharmacol. 1979 Aug;8(2):143–148. doi: 10.1111/j.1365-2125.1979.tb05812.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Uusitupa M., Siitonen O., Härkönen M., Gordin A., Aro A., Hersio K., Johansson G., Korhonen T., Rauramaa R. Metabolic and hormonal response to physical exercise during beta 1-selective and non-selective beta-blockade. Horm Metab Res. 1982 Nov;14(11):583–588. doi: 10.1055/s-2007-1019087. [DOI] [PubMed] [Google Scholar]
  15. Wilcox R. G., Hampton J. R. Comparison between atenolol and nadolol in essential hypertension at rest and on exercise. Br J Clin Pharmacol. 1982 Jun;13(6):841–846. doi: 10.1111/j.1365-2125.1982.tb01876.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. William-Olsson T., Fellenius E., Björntorp P., Smith U. Differences in metabolic responses to beta-adrenergic stimulation after propranolol or metoprolol administration. Acta Med Scand. 1979;205(3):201–206. doi: 10.1111/j.0954-6820.1979.tb06031.x. [DOI] [PubMed] [Google Scholar]
  17. Williams M. E., Gervino E. V., Rosa R. M., Landsberg L., Young J. B., Silva P., Epstein F. H. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med. 1985 Mar 28;312(13):823–827. doi: 10.1056/NEJM198503283121304. [DOI] [PubMed] [Google Scholar]
  18. Wynne R. D., Crampton E. L., Hind I. D. The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers. Eur J Clin Pharmacol. 1985;28(6):659–664. doi: 10.1007/BF00607911. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES